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Lymphedema remains a poorly understood entity that can occur after lymphadenectomy. Herein, we will review
the pathogenesis of lymphedema, diagnostic modalities and the natural history of extremity involvement. We will
review the incidence of upper extremity lymphedema in patients treated for breast malignancies and lower
extremity lymphedema in those treated for gynecologic malignancy. Finally, we will review traditional treatment
modalities for lymphedema, as well as introduce new surgical treatment modalities that are under active
investigation.
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Definition, classification and pathogenesis of
lymphedema
Along with the arterial and venous vasculature, the lym-
phatic system represents an important component of the
circulatory system. Lymphatic channels primarily regulate
the flow of fluid in the interstitium [1]. Under normal con-
ditions, venous capillaries reabsorb 90% of the fluid in the
tissues, and lymphatic channels absorb the remaining 10%
of lymph fluid, proteins and other molecules [2]. Lym-
phatic fluid then passes to the regional lymph node ba-
sins. Ultimately, this fluid is transported back to the left
subclavian vein to enter the venous system via the tho-
racic duct.
Lymphedema results from lymphatic insufficiency and
inadequate lymph transport [3]. Decreased lymph trans-
port causes an accumulation of protein-rich interstitial
fluid, leading to distention, proliferation of fatty tissue and
progressive fibrosis. Thickening of skin and hair loss may
subsequently occur. Progressive lymphedema without ad-
equate management can lead to functional impairment,
compromised quality of life and physical deformity.* Correspondence: pankaj.tiwari@osumc.edu
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reproduction in any medium, provided the orClinically, lymphedema is noted as swelling of the in-
volved extremity. The head, neck, breast, or genitalia may
also be affected [4-6].
Lymphedema is generally classified as either primary
or secondary.
Primary lymphedema is related to congenital malfor-
mation of the lymphatic channels. It can result from any
one of a number of disorders that may be sporadic or
hereditary. The estimated prevalence of primary lym-
phedema is 1.15 in 100,000 persons under the age of 20
[5]. In children, the two main causes are Milroy disease
and lymphedema distichiasis [3].
Secondary lymphedema is a consequence of surgical
removal or damage to lymph nodes, post-radiation fibro-
sis of the lymph nodes, trauma, or infection [6]. Upper
extremity lymphedema is commonly associated with the
treatment of breast cancer. The degree of lymphedema
correlates with the number of lymph nodes that have
been removed and the extent of radiation treatment to
the axillary region. Lower extremity lymphedema is seen
in patients treated for gynecologic malignancy and pros-
tate cancer, as well as melanoma and lymphoma [7].
Most patients develop lymphedema within three years of
treatment [8]. In addition to cancer treatment-related
lymphedema, side effects of advanced diseases, such as
congestive heart failure, neurological and liver diseasetd. This is an Open Access article distributed under the terms of the Creative
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phedema. An increase in the bariatric population has
also seen an increase in lymphedema incidence [9].
Lymphedema caused by the parasite Wucheria bancrofti
and transmitted by mosquitoes, remains the most com-
mon cause of lymphedema worldwide.
Unfortunately, no strategies employed to prevent the
onset of lymphedema have proven fruitful to date. New
clinical data suggest that some patients may have a pri-
mary predisposition to lymphedema; however, in these
instances, lymphedema does not become clinically evi-
dent until after the occurrence of some secondary
eliciting event [6]. Lymphedema tarda is defined as new
onset lymphedema after the age of 35. It is often associ-
ated with an eliciting event such as trauma or infection.
Once established, lymphedema may progress to a chronic
condition. ‘Chronic lymphedema’ is generally categorized
as lymphedema persisting for more than three months.
Prevalence estimates for chronic lymphedema are between
1.3 and 1.5 per 1,000.
At the cellular level, lymphedema is a complex inter-
play of lymphangiogenesis, inflammation, fibrosis and
lipid metabolism [10]. Recent work has demonstrated
that inflammatory responses may play a significant role
in lymphedema pathogenesis. Lymphatic stasis results in
CD4(+) T-cell inflammation and T-helper 2 (Th2) diffe-
rentiation. Using mice deficient in T cells or CD4(+) cells,
Avraham et al. have shown that the inflammatory re-
sponse is necessary for the pathological changes of
lymphedema, including fibrosis, adipose deposition
and lymphatic dysfunction [11]. Such work carries the
potential to identify better the molecular mechanisms
underlying the progressive fibrosis associated with
chronic lymphedema. Intervention at the signal trans-
duction level may prevent and/or reverse the develop-
ment of fibrosis that occurs in chronic lymphedema.
Diagnosis of lymphedema
The diagnosis of lymphedema is typically made after a
thorough history and physical examination. Initial stages
of lymphedema begin with a soft pitting edema, usually
in a unilateral extremity. Over time, chronic edema
stimulates inflammatory changes in the subcutaneous
space. These changes result in skin induration and thick-
ening ultimately developing into a non-pitting edema
with fibrotic changes of the skin and subcutaneous
tissues.
The lymphedematous extremity is typically assessed in
a clinic setting. Evaluation involves serial measurements
over time to assess changes in the status of the involved
extremity. If the contralateral extremity is uninvolved,
measurements of this extremity are used as a control.
There can be great inter-observer variability if the ana-
tomic points of measurement are not standardized. Atour institution, the upper extremity is measured as follows:
middle finger, proximal to the proximal interphalangeal
(PIP) joint and proximal to the metacarpophalangeal
(MCP) joint; wrist proximal to the styloid; forearm four
inches distal to the olecranon; elbow extended at crease;
mid upper arm four inches proximal to the olecranon; ax-
illa eight inches proximal to the olecranon. The lower ex-
tremity is measured as follows: instep proximal to the
metatarsophalangeal (MTP); ankle proximal to the malle-
oli; calf six inches distal to the infra-patellar border; knee at
the popliteal fold; mid-thigh six inches proximal to the
superior patellar border; groin eight inches or ten
inches superior to the superior patellar border. Associ-
ated pain and fatigue are also routinely recorded in the
clinical assessment. Lastly, all patients are given the
Lymphedema Breast Cancer Questionnaire (LBCQ) to
fill out, representing a validated tool for the assessment
of lymphedema symptoms [12].
When imaging is used, the most common modality for
diagnosis is indirect radionuclide lymphoscintigraphy
[13,14]. This procedure requires intradermal or subcuta-
neous injection of an appropriate radiolabeled tracer
(99mTc-antimony sulfide colloid or 99mTc-labeled human
serum albumin). Criteria for the diagnosis of lymphatic
dysfunction include: (1) delayed, asymmetric or absent
visualization of regional lymph nodes; (2) asymmetric
visualization of lymphatic channels; (3) collateral lym-
phatic channels; (4) interrupted vascular structures;
and (5) visualization of the lymph nodes of the deep
lymphatic system. The presence of ‘dermal back-flow’
is considered abnormal. It is interpreted to represent
the extravasation of lymph fluid from the lymphatics
into the interstitium as a result of lymphatic and/or
venous hypertension [15].
Beyond lymphoscintigraphy, magnetic resonance im-
aging and computerized axial tomography have clinical
utility. These imaging techniques permit objective docu-
mentation of the structural changes caused by lymphedema
[16,17]. Recent advances in the magnetic resonance ap-
proach have improved the visualization of lymphatic vascular
anomalies in both nonenhanced [18] and contrast-enhanced
[19] applications.
At our institution, we have utilized a protocol similar
to that described by Arrive et al. [20]. This protocol is
similar to magnetic resonance (MR) lymphography of
the retroperitoneal area and does not involve contrast in-
jection. The MR lymphography utilizes a three-dimensional
high spatial-resolution, fast spin-echo sequence. The main
advantage of a three-dimensional isotropic MR lymphogra-
phy protocol is to capture thinner section source images.
Thinner images allow for the optimal processing of image
data in order to obtain maximum intensity projection (MIP)
images and multiplanar reformatted (MPR) images. MR
lymphography also allows the potential advantage of a
Figure 1 Left upper extremity lymphedema in a patient treated
for breast cancer with modified radical mastectomy and
axillary radiation treatment.
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potentially allowing for the calculation of extremity
volumes.
The use of indocyanine green lymphography has emerged
as an important imaging technique in the work-up of
patients with upper extremity and lower extremity
lymphedema. Indocyanine green lymphography allows
pathophysiological lymphedema severity staging in real-
time without radiation exposure. This technique has also
been reported to be useful for intraoperative navigation for
lymphatic surgery. With progression of secondary arm/leg/
facial lymphedema, lymphography findings change from a
normal ‘linear’ pattern to an abnormal ‘dermal backflow’
pattern. With this imaging, dermal backflow patterns can
be visualized as a mild dermal backflow ‘splash’ pattern,
moderate dermal backflow ‘stardust’ pattern, or severe der-
mal backflow ‘diffuse’ pattern. Progression of the lymphog-
raphy pattern may correspond to the pathology of the
lymphatic system [21-25].
Bioelectric impedance spectroscopy analysis is an
emerging diagnostic technique for the clinical evaluation
of lymphatic edema. The technique uses resistance to
electrical current in comparing fluid compartments within
the body [26]. It has been considered as a cost-effective
and reproducible method for evaluating patients with
suspected lymphedema [26]. The technique allows for
noninvasive quantification of extracellular fluid in the ex-
tremities. The technique is sensitive and reproducible and
is likely to find increasing application in the early detec-
tion and management of lymphedema.
Finally, innovative biomarkers have also been deve-
loped to facilitate early-stage diagnosis. Microarray-based
transcriptomics of human skin have been developed to
identify patients with lymphedema. Such multi-variable
biomarker panels should sensitively discriminate human
lymphedema subjects from normal individuals [10].
Review
Breast cancer-related lymphedema
Breast cancer, including all cases of invasive and in situ
carcinoma, is newly diagnosed in more than 296,000
women each year in the United States [27]. These
women subsequently undergo treatment that can include
surgical intervention, chemotherapy, radiation therapy,
anti-estrogen therapy and/or targeted therapy [27]. Treat-
ments are effective, with almost three million survivors of
invasive breast cancer currently living the United States
[28]. Nevertheless, breast cancer survivors may experience
postoperative and long-term complications as a result of
their treatment.
Lymphedema of the upper extremity is a well-recognized,
long-term complication of either axillary lymph node dis-
section (ALND), or even of sentinel lymph node (SLN) bi-
opsy alone [28]. The reported incidence of breast cancerrelated lymphedema with ALND varies widely, ranging
from 2% to 56% [29-34]. Reports have demonstrated
decreased quality of life outcome measures as well as
psychosocial difficulties that may include body image
disturbances, permanent uncertainty and adverse ef-
fects on relationships [35-37]. Further, lymphedema
can interfere with activities of daily living by causing a
restriction in range of motion, pain, increased skin ten-
sion, recurrent infection, extremity swelling and the
patient’s perception of the feeling of heaviness in the
affected extremity [38-40]. Impairment of function af-
fects the ability to work and participate in sporting ac-
tivities [38]. Skin changes, such as thickening and hair
loss, may also occur. While patients may develop
lymphedema at any time following their breast cancer
treatment, 70% of affected individuals report that they
have onset of symptoms within one to two years [31]
(Figure 1).
Multiple staging systems exist regarding lymphedema
of the upper extremity [41,42]. The International Society
of Lymphology describes three stages of lymphedema.
The staging is as follows: stage 0, latent condition with
no evident swelling but impaired lymph transport;
stage 1, early accumulation of fluid that subsides with
limb elevation; stage 2, limb elevation alone does not
reduce swelling and pitting may or may not be present;
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only refer to the physical condition of the extremity; a
more detailed staging system needs to be developed to
include pathology [42].
Risk factors for lymphedema development have been
extensively studied and are widely reported in the litera-
ture. In relation to the breast cancer itself, a larger
tumor size [43] and location in the upper outer quadrant
[44] have been reported as risk factors. The Iowa
Women’s Health Study of 1,287 patients found that a
more advanced tumor stage, larger number of excised
nodes and having tumor positive nodes were positively
associated with lymphedema development [31]. Physical
functioning was also found to be significantly lower in
patients with cancer metastasis [45].
The wide range of reported incidence of breast
cancer-related lymphedema is largely due to variations
in treatment regimens, with some therapies having sig-
nificantly higher rates of lymphedema development
[31,32,43,46-48]. In a study of 516 patients, Veronesi
et al. showed a decreased incidence of lymphedema in
patients receiving SLN biopsy compared to those receiv-
ing ALND [33]. More recently, the National Surgical
Adjuvant Breast and Bowel Project (NSABP) B-32 trial
examined breast cancer related lymphedema at a three-
year follow up of 1,975 patients with ALND and 2,008
patients with SLN biopsy. They concluded that lym-
phedema incidence increased with ALND when com-
pared to SLN biopsy (14% versus 8%) [34]. Further, as
the number of lymph nodes removed increases, so does
the risk and severity of lymphedema [30,49]. Radiation
to the breast or to the axillary lymph nodes also in-
creases the risk and severity for lymphedema [30,32,49].
The combination of ALND and radiation has a higher
incidence for lymphedema development than with either
treatment alone [30]. Gartner et al. studied the effect of
chemotherapy by examining different combinations of
surgery and radiation therapy, with and without chemo-
therapy [38]. These authors have demonstrated that re-
gardless of treatment regimen, chemotherapy increases
the risk of lymphedema development [50]. It should be
noted that an important factor associated with the wide
range of reported lymphedema incidence is the subject-
ive nature of the diagnostic criterion that is used for
lymphedema. Some studies rely on >1 cm of extremity
circumference difference between extremities while
other studies rely on ‘subjective symptoms’ as the chief
diagnostic criterion.
Breast cancer reconstruction has been implicated as a
possible contributor to development of lymphedema.
However, studies have demonstrated that these concerns
are unfounded [51,52]. Interestingly, a recent study has
shown that breast reconstruction is associated with de-
creased rates of lymphedema development [53]. Cardet al. showed that patients who did not undergo recon-
struction, either with autologous tissue or implant based,
were significantly more likely to develop breast cancer
related lymphedema, 9.9% versus 3.7% [53].
Patient factors associated with breast cancer related
lymphedema include body mass index (BMI) and age
[30,31,45,54-56]. The Iowa Women’s Health Study found
that a higher baseline BMI, larger waist and hip circum-
ference and a poorer general state of health were posi-
tively associated with lymphedema development [31].
Ridner et al. report that patients with BMI >30 at the
time of treatment are 3.6 times more likely to develop
lymphedema [54]. The effect of age is more controver-
sial. In a survey study of 3,253 patients, Gartner et al.
reported that younger age was significantly related to
more severe symptoms [38]. Conversely, Park et al.
found that upper extremity function correlated to age,
with older patients having poorer scores on the Disabil-
ities of Arm Shoulder and Hand outcome measure [45].
These findings were corroborated by Pezner et al. who
found the incidence of lymphedema was 25% at age
greater than 60 years and 7% at age less than 60 years
[57]. Additional lifestyle risk factors that have been
reported include a sedentary lifestyle [58].
Some have proposed that patient factors and cancer
treatment can only partially explain the risk of lym-
phedema development and that inherited genetic sus-
ceptibility must therefore play a role [59]. In one study
of 120 patients, those with SNPs in the receptor genes,
VEGFR2, VEGFR3 and RORC, were significantly more
likely to have developed lymphedema [59]. Genetic
predisposition must be further studied to clarify this
possible association.
While risk factors have been identified, the mechanism
by which they contribute to lymphedema development is
less clear. Surgery physically alters lymphatic channels,
decreasing the ability to drain lymphatic fluid and caus-
ing accumulation of fluid and tissue protein [31]. Radi-
ation increases endothelial proliferation and fibrosis.
Tumors induce an inflammatory state, and chemothe-
rapy and radiation can further exacerbate this host-
driven inflammatory response [60]. Advanced age has
been postulated to increase the risk of lymphedema due
to a decrease in the number of lymphovenous anasto-
moses that may open in response to increased extremity
interstitial pressure, thereby reducing compensatory
mechanisms. While many hypotheses exist, further re-
search is needed to clarify the pathophysiology of breast
cancer related lymphedema development.
Although no risk reduction strategies have been defini-
tively substantiated, strategies include the avoidance of
needle sticks and blood pressures in the ipsilateral upper
extremity and prophylactic actions, such as wearing
compression garments during air travel [47]. Prospective
Figure 2 Right lower extremity lymphedema in a patient
treated for endometrial cancer with lymphadenectomy and
radiation treatment.
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lymphedema and implement treatment at an earlier
stage [61]. Advocates of this program believed that earl-
ier detection and treatment would decrease the need for
intensive rehabilitation and also be cost-effective. Using
the prospective surveillance model with interval screen-
ing, the cost to manage early-stage lymphedema per pa-
tient per year was found to be $636.19, compared to the
cost to manage late-stage lymphedema in a traditional
referral based model which was $3,124.92 [61].
Among breast cancer patients, a general lack of know-
ledge regarding lymphedema risk and risk reduction
practices exists [62,63]. Kwan et al. conducted a survey
study of 389 patients with invasive breast cancer to de-
termine their level of lymphedema awareness. They
found that on a scale of 0 to 7, the median lymphedema
awareness score was 4. Further, older age was signifi-
cantly associated with a lower score [62]. Other studies
have shown that increased knowledge of lymphedema
correlates with higher risk for development [64,65].
However, those patients with lymphedema who received
adequate information had significantly reduced symp-
toms [64]. Nurse assisted education and exercise have
been shown to decrease the degree of lymphedema
[47,66]. Programs have been implemented nationwide to
increase patient knowledge [67]. The American Lymph-
edema Framework Project is a national initiative devel-
oped under the leadership of clinical experts and
researchers in the field of lymphedema. While the pro-
ject has multiple goals, they have prioritized developing
and providing appropriate practice-based lymphedema
educational programs for breast cancer patients [68].
Gynecologic oncology perspective on lower extremity
lymphedema
The American Cancer Society estimates that there are
more than one million gynecologic cancer survivors cur-
rently living in the United States [69]. As this number
continues to grow, more awareness of long-term compli-
cations related to the disease and its treatment are
gaining attention. Lower extremity lymphedema (LEL)
has been largely understudied and is one of these unin-
tended consequences. Currently, data on LEL as a result
of gynecologic malignancies has been limited to retro-
spective studies and has been hindered due to a lack of
standard diagnostic evaluations and assessments, making
the diagnosis elusive [70,71]. Furthermore, co-morbid
conditions, such as deep venous thrombosis, congestive
heart failure, and medications, may cause lower extremity
swelling making evaluation for LEL more challenging [72].
However, when LEL is diagnosed, the impact on pa-
tients can be substantial, both physically and psycho-
logically. After treatment for gynecologic malignancies,
LEL has been reported to affect a woman’s ability tofunction, including a decreased ability to perform acti-
vities of daily living and loss of work [73-75]. Additional
physical consequences of LEL include leg discomfort
secondary to heaviness, pain and skin tightness, as well
as sexual difficulties [74,76,77] (Figure 2). In regard to
psychological effects, gynecologic cancer survivors with
LEL consistently report a decreased quality of life and
self-confidence as well as increased anxiety and depres-
sion [73,74,78].
As cancer and its treatment are the most common cause
for the development of secondary lymphedema in the
United States, understanding its true impact is necessary
[79]. In patients who have been treated for gynecologic ma-
lignancies, LEL risks may be categorized in the following
groups: (1) preoperative factors (for example, genetic pre-
disposition, obesity, age, race, nutritional status); (2)
intraoperative factors (for example, number of lymph nodes
removed, location of nodal dissection and procedures
performed); and (3) postoperative factors (for example, ad-
juvant treatment, limb infection/trauma). Identification of
risk factors and risk stratification may help gain insight into
preventive measures and early detection/intervention for
patients who are at increased risk for LEL [79]. Therefore,
the need to gain insight into this condition is imperative.
The purpose of this section is to provide a review of the
current literature and overview of LEL in women with
gynecologic cancers.
Groin dissection and vulvar cancer
The primary management of vulvar cancer consists of
radical surgical resection of the vulvar mass and groin or
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tion is the lower extremity counterpart to axillary lymph
node dissection, this procedure is correlated with the
highest risk of LEL in gynecology, ranging from 25% to
67% [75,80-82]. Therefore, although it only affects an es-
timated 3,500 women per year in the United States, this
treatment-related morbidity has been most extensively
studied in vulvar cancer compared to other gynecologic
cancers [83].
Risk factors and risk reduction
Consistent with other disease sites, one report noted
that the removal of a higher number of lymph nodes,
particularly more than six, was associated with a higher
likelihood of LEL development [84]. Other factors in-
creasing the risk of LEL include development of infec-
tion, and, interestingly, staple closure of the incision
[80,81]. Other suggested risk factors include older age
and diabetes [81]. Furthermore, high output from the
groin drain was associated with higher risk of LEL and
wound breakdown [81].
Efforts to reduce the rates of LEL in patients undergo-
ing surgery for vulvar cancer have also been conducted.
One of the largest impacts in reducing morbidity was
seen with the incorporation of a three-incision technique
when compared to the en bloc resection. This surgical
modification, along with sparing of the saphenous vein,
has significantly reduced the rate of LEL as well as other
morbidity from this procedure [81,82,85]. In further ef-
forts to reduce the association of surgical complications,
particularly LEL, a randomized prospective trial using
suture closure with or without the addition of fibrin
sealant following groin dissection was evaluated in
women undergoing surgery for vulvar cancer [80]. Un-
fortunately, rates of LEL based on limb measurements
were high, exceeding 60% in both groups, and the use of
fibrin sealant did not reduce LEL, leading to the need
for alternative measures [80].
An area gaining rapid interest is the use of SLN biopsy
in place of a complete lymph node dissection. Based on
the data in the breast cancer literature, SLN biopsy has
been successfully used in select cases with a reduction in
surgical morbidity without compromising oncologic out-
comes [86]. SLN biopsy has been shown to be a safe al-
ternative to a full groin dissection in women with vulvar
cancer, with similar groin recurrence rates [87,88]. More
impressively, the rate of LEL in the SLN biopsy group
was 1.9% compared to 25% in those undergoing a full
dissection and improved surgical related outcomes
[88,89]. As these methods become more commonly uti-
lized and evaluated, the true impact of SLN biopsy may
result in a change in the standard of practice, signifi-
cantly reducing rates of LEL from the treatment of gyne-
cologic malignancies.Pelvic lymph node dissection and cervical, uterine and
ovarian cancers
For malignancies involving the cervix, uterus and ovar-
ies, primary therapy consists of surgical intervention
with removal of the primary organ involved and the
adjacent structures, along with a pelvic lymph node
dissection (PLND) +/− para-aortic lymph node dissec-
tion [71,72,90]. Though less studied than in women
undergoing groin dissection for vulvar cancer, LEL as a
consequence of PLND has also been described. Retro-
spective studies report that the incidence of LEL in this
group of patients ranges from 2.4% to 41% and has
been shown to be significantly higher than in the gen-
eral population [71,72,90-96].
Risk factors and risk reduction
Similar to groin dissection, the extent of lymph node
dissection has consistently been shown to correlate with
the development of LEL, although the number of lymph
nodes ranges from 10 to 31 lymph nodes [71,72,92,97].
Another constant factor is the removal of the circumflex
iliac nodes during a PLND, which breeches the groin
lymph nodes and would expectantly result in higher
rates of LEL as seen with the treatment for vulvar cancer
[92,93,98,99]. Although not universal, a majority of stud-
ies report increased risk of LEL following surgery when
compounded with radiation therapy [71,91,99-101].
Exacerbating factors for LEL are similar to those
reported in upper extremity edema and those associated
with groin dissection and include prolonged activity/
standing and heat exposure [71]. However, with regard
to other potential risk factors, such as age, retrospective
studies have shown variable results [72,92,102]. Al-
though obesity is independently associated with LEL, re-
ports in gynecologic cancers have been less reliable
[71,72,92,94,103].
Efforts to reduce the development of LEL secondary to
PLND have been less extensively evaluated than its groin
counterpart. In this forum, Fujiwara and colleagues eva-
luated the use of omentoplasty/omentopexy into the
retroperitoneal nodal basins. As a result of this surgical
procedure, the authors noted reduced rates of lymph-
edema and lymphocele in women with cervical and
endometrial cancers compared to historical controls
[104]. Another surgical modification, although most re-
search has been conducted in vulvar cancer, is the role
of SLN biopsy in place of PLND. Although larger studies
are ongoing, the use of SLN biopsy mapping for cervical
and endometrial cancer has demonstrated promising
preliminary results [105,106]. As these methods are eval-
uated further and are more commonly utilized, the true
impact of SLN biopsy may result in a change in the
standard of practice, significantly reducing rates of LEL
from the treatment of gynecologic malignancies.
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There are a multitude of factors limiting the understan-
ding of LEL from gynecologic malignancies, regardless
of the inciting cause of LEL (groin dissection or PLND).
First, there is a lack of awareness of LEL, by both pro-
viders and patients, resulting in disregard of the condition
or a delay in referral for treatment [70,71]. Secondly, in-
consistent measurement techniques and lack of definition
criteria have further hindered the ability to diagnose LEL
[71,107]. Use of limb volume measurement with water
displacement has been used; however due to feasibility is-
sues, it is often limited to certain environments. Many
studies have utilized lower limb circumferential measure-
ments at pre-designated intervals comparable to assess-
ments used in the literature regarding upper extremity
lymphedema evaluations [108,109]. One of the most com-
monly reported tools is the use of subjective diagnosis
based on the presence of symptoms. Carter and colleagues
recently demonstrated that the Gynecologic Cancer
Lymphedema Questionnaire (GCLQ) may be used as an
effective tool to identify survivors with LEL after gyneco-
logic cancer treatment [79].
In addition to direct measurements and question-
naires, imaging has also been evaluated. Although not
practical for routine use, Lu et al. recently reported the
presence of increased lymphatic vessels in affected ex-
tremities using MR lymphography to evaluate LEL se-
condary to gynecologic malignancies [110,111]. Regardless
of which method is used, the need for improved and con-
sistent diagnostic methods is apparent. Another compli-
cating factor regarding diagnosis of LEL is the variable
time of onset. Most studies report a diagnosis of LEL
within the first year (median four to six months) after
treatment, with 5% diagnosed within the first month
[71,72,91,111]. However, long-term assessment should be
performed as up to 20% of LEL cases are diagnosed after
the first year [70,100].
Future directions for lower extremity lymphedema
As awareness is increasing, efforts to address all aspects of
LEL secondary to gynecologic cancers are improving. The
incorporation of quality of life assessments, particularly
those that focus on LEL, in gynecologic oncology studies
will help develop our understanding of the impact of this
condition. Understanding the incidence and developing a
definition and consistent measure for LEL is critical. Cur-
rently, the Gynecologic Oncology Group (protocol 244) is
conducting a prospective trial using a standardized objec-
tive limb measurement as well as subjective measure-
ments/quality of life assessments in women undergoing
surgery for vulvar, cervical or uterine cancers. Although
the results will not be available for some time, this study is
providing overdue attention to an important issue in sur-
vivors of gynecologic malignancies.Treatment modalities for lymphedema
When lymphedema is diagnosed, regardless of disease
site, management is extremely variable, and currently
there are no standard recommendations [70]. This lack
of information results in inadequate or delayed manage-
ment and, most likely, contributes to the decreased qua-
lity of life experienced by patients with LEL [70,71,74].
The state-of-the-art therapeutic approach to lymph-
edema relies upon physiotherapeutic techniques. Com-
plex decongestive physiotherapy (CDPT) is designed to
reduce limb volume and maintain the skin health and
may stimulate lymphatic transport and facilitate the re-
moval of retained interstitial proteins [112]. CDPT relies
on a lymphatic-specific massage technique termed man-
ual lymphatic drainage (MLD) [113]. A mild degree of
manual tissue compression enhances filling of the cuta-
neous lymphatics and improves dilation and contraction
of the lymphatic vessels. MLD may also recruit pathways
for lymph flow and enhance the development of accessory
lymph pathways.
In addition to MLD, the CDPT approach includes skin
care, exercise and external compression. Short stretch
bandaging compression creates a multilayer compart-
ment that augments lymphatic contraction and flow
[114]. During active tissue compression, abnormally in-
creased ultrafiltration is reduced leading to improved
fluid reabsorption. Once edema volume has decreased,
maintenance of the therapeutic benefits will require fit-
ted elastic garments. Nocturnal compression may also
be required. Relatively inelastic sleeves and garments
that transmit 40 to 80 mm Hg of compressive pressure
will prevent fluid re-accumulation after successful CDPT.
Garments must be fitted properly and replaced every three
to six months.
While CDPT benefits the majority of patients with
lymphedema, the interventions are labor-intensive, time-
consuming and expensive. The potentially uncomfortable
and visible garments may adversely affect the patient’s
quality of life. In addition, the interventions are not uni-
formly successful. Most patients achieve adequate edema
control, but some may require additional interventions
[70]. Intermittent pneumatic compression has also been
shown to augment the decompressive effects of standard
therapies.
Principles of the surgical management of lymphedema
Multiple surgical interventions for the treatment of
lymphedema have been described, and any surgical
intervention must be premised on well-defined indica-
tions. The typical surgical candidate has failed conserva-
tive therapy with an increase in the size and weight of
the extremity and an impairment of extremity function.
Patients who are recalcitrant to compression techniques
may experience recurrent lymphangitis. In our practice,
Figure 3 Design for submental lymph node flap based on the
submental vessels branching from the facial vessels. The flap
design is identical to a submental flap as used for head/neck
reconstruction.
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of lymphangitis per year requiring the use of either oral
or intravenous antibiotics are candidates for surgical
intervention. Fibrofatty replacement of the subcutaneous
tissue may worsen lymphatic fluid return and may limit
the potential for successful surgical intervention. Al-
though the gold standard for management of extremity
lymphedema remains medical and includes decom-
pressive measures, surgical treatments, including exci-
sion, lymphaticovenular bypass and vascularized lymph
node transfer, are under active investigation.
Excisional techniques have been used since the 1910s
and include debulking and liposuction [114]. Debulking
surgery involves removal of lymphedematous adipose
tissue down to fascia, followed by skin grafting or pri-
mary closure after elevation of skin flaps [114,115].
While earlier reports of this technique demonstrate its
suboptimal outcomes and high complication rates, more
recent reports show debulking can have good functional
outcomes and minimal complications [115-120]. Salgado
reports a 21% volume reduction using surgical excision
in the upper extremity at more than one year post-
operation [115]. Liposuction has been utilized more re-
cently to remove subcutaneous lymphedematous fat and
has proven to be effective for volume reduction
[121-128]. In their study of 37 patients, Damstra et al.
reported a 118% volume reduction of the upper extrem-
ity at one year following suction-assisted lipectomy
[121]. Long-term results have also been reported with an
upper extremity volume reduction of 101% at five years
[122]. An advantage, aside from volume reduction, is in-
creased skin blood flow which may decrease the incidence
of cellulitis [124]. The most common disadvantage of this
method includes transient numbness. Debulking surgeries,
including excision and liposuction, effectively reduce
lymphedematous volume, but may have the potential to
violate the remaining, functional lymphatic structure. As a
result, compression therapy is often necessary on a long-
term basis.
Lymphaticovenular bypass is another surgical treatment
of lymphedema. Supermicrosurgery with the aid of high
power microscopy has been used to anastomose lymphatic
channels to subdermal venules of less than 0.8 mm in dia-
meter [114,129-134]. In ‘microsurgical lymphaticovenous
anastomosis’, lymphatic vessels with surrounding tissue are
inserted into a vein (>2 mm), and anastomosis site
thrombosis is inevitable when venous reflux occurs. In
‘supermicrosurgical lymphaticovenular anastomosis’, a
lymphatic vessel is anastomosed to a venule or smaller
vein (approximately 0.5 mm) in an intima-to-intima
coaptation manner and can prevent anastomosis site
thrombosis even when venous reflux occurs [129-140].
This method is based on two concepts. Firstly, subder-
mal lymphatics are less affected by lymphedema andcan be used for bypass. Secondly, pressure in subdermal
venules is low and, therefore, venous backflow is mini-
mized [130]. Chang prospectively utilized this technique
in 20 patients with upper extremity lymphedema [130].
He created two to five anastomoses for each patient. Nine-
teen patients reported symptom improvement following
surgery, and a mean volume reduction of 35% was seen at
one-year post-operation [130].
An alternative method has been proposed by Campisi
et al. The technique consists of anastomosing lymphatic
vessels to a collateral branch of a main vein and
confirming the functionality of the valvular apparatus. A
functional valve will allow for unidirectional lymphatic
flow, thereby limiting the potential for reflux of blood
and anastomotic thrombosis. Healthy-appearing lym-
phatics found at the site of surgical operation are di-
rectly introduced into the vein by a U-shaped stitch and
then fixed to the vein cut-end by additional stitches be-
tween the vein border and the perilymphatic adipose tis-
sue [41]. In the largest retrospective study of 1,800
patients over 10 years, Campisi demonstrates a volume
reduction of 67% and notes that 85% of patients were
able to discontinue conservative treatment modalities [134].
Disadvantages to this procedure are that it is technically
challenging and results are currently unpredictable [140].
Submental lymph 







Figure 4 Intraoperative view of cervical lymph node flap (level I)
identifying submental vessels and facial nerve.
Figure 6 Patient with a history of vulvar carcinoma who has
undergone superficial lymphadenectomy and resulting lower
extremity lymphedema. Incision design for elevation of
vascularized lymph node flap based on thoracodorsal vessels and
incision design for abdominal incision for inset of flap (black arrows).
Green arrows indicate sites of injection of indocyanine green to
identify lymph nodes draining the chest for inclusion in the flap. Red
arrow indicates the site for inset of the vascularized lymph node flap
above the muscular fascia in the region of superficial lymphadenectomy.
The patient had undergone technetium injection into the left hand the
day prior to surgery in order to identify lymph nodes draining this
extremity (‘reverse lymphatic mapping’).
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invasiveness and a low rate of complications [131].
The most recent advancement in surgical lymphedema
treatment is vascularized lymph node transfer. Healthy
lymph nodes, artery and vein are transplanted from an
unaffected axilla, groin or cervical/neck to the affected
area of lymphedema [141-145] (Figures 3, 4, 5, 6, 7).
One hypothesis is that the transferred lymph nodes act
as a pump and suction pathway for lymphatic clearanceFigure 5 Design of a planned cervical lymph node flap (level V)
based on transverse cervical vessels. Depicts sites of indocyanine
green injection for intraoperative lymph node identification. The flap is
based on the transverse cervical vessels located at the junction of the
medial and middle thirds of the clavicle.[142]. Lin et al. report, at more than four years post-
operation, a 51% reduction in upper extremity volume
when transferring groin lymph nodes to the wrist [142].
Cheng et al. report a reduction in circumference of more
than 60% in the lower extremity when utilizing submental
lymph nodes transferred to the ankle [141]. In Becker’s
study, of 24 patients with groin lymph node transfer to the
axilla for upper extremity lymphedema, physiotherapy was
able to be discontinued in 62.5% of patients [145].
Development of lymphedema in the donor site remains
a concern. Initial literature demonstrated morbidity to be
minimal [143]. Recent reports suggest a higher incidenceFigure 7 Intraoperative view of lymph node flap based on
thoracodorsal artery and vein. The picture depicts the lower chest
thoracic lymph nodes located at Level III axillary lymph node
position. These lymph nodes did not take up technetium, thereby
avoiding the extremity drainage basin.
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In studying patients who had undergone vascularized
lymphatic transfer, Vignes et al. found that six of 26 pa-
tients developed chronic lymphedema, defined as ≥2 cm
difference versus the contralateral side [146]. This donor
site lymphedema remains a significant concern and any
transfer of VLNs (vascularized lymph nodes) must include
an evaluation of lymph nodes draining the donor site.
Reverse lymphatic mapping is a technique that has
been suggested to differentiate the lymph node basins
draining an extremity from those that may be useful for
vascularized lymph node harvest and transfer [147]. The
technique is similar to the axillary reverse mapping that
has been presented by Klimberg et al. [148]. Reverse
lymphatic mapping builds on the principle of differential
identification of lymph node basins with separate drainage
patterns. Technetium can be injected into the dorsal
webspace of an extremity similar to the injection technique
that is performed during lymphoscintigraphy. Simultan-
eously, lymphazurin blue may be injected into either trunk
or groin nodal basins. By differentiating lymph nodes that
drain an extremity from those amenable to vascularized
lymph node transfer, this technique may reduce the inci-
dence of secondary lymphedema at the donor site.
Conclusions
The management of lymphedema remains a complex en-
tity that requires knowledge of the underlying pathophysi-
ology. Patients with breast or gynecologic malignancy are
at risk for the development of lymphedema, particularly in
the setting of lymphadenectomy and/or radiation treat-
ment. Although management with physical therapy re-
mains the primary treatment, exciting new surgical
treatments are under active investigation.
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